Literature DB >> 21070606

L-selectin is dispensable for T regulatory cell function postallogeneic bone marrow transplantation.

M J Carlson1, L M Fulton, J M Coghill, M L West, J E Burgents, Y Wan, A Panoskaltsis-Mortari, T F Tedder, B R Blazar, J S Serody.   

Abstract

In murine models, the adoptive transfer of CD4(+) /CD25(+) regulatory T cells (T(regs) ) inhibited graft-versus-host disease (GvHD). Previous work has indicated a critical role for the adhesion molecule L-selectin (CD62L) in the function of T(regs) in preventing GvHD. Here we examined the capacity of naive wild-type (WT), CD62L(-/-) and ex vivo expanded CD62L(Lo) T(regs) to inhibit acute GvHD. Surprisingly, we found that CD62L(-/-) T(regs) were potent suppressors of GvHD, whereas CD62L(Lo) T(regs) were unable to inhibit disease despite being functionally competent to suppress allo T cell responses in vitro. Concomitant with improved outcomes, WT and CD62L(-/-) T(regs) significantly reduced liver pathology and systemic pro-inflammatory cytokine production, although CD62L(-/-) T(regs) were less effective in reducing lung pathology. While accumulation of CD62L(-/-) T(regs) in GvHD target organs was equivalent to WT T(regs) , CD62L(-/-) T(regs) did not migrate as well as WT T(regs) to peripheral lymph nodes (PLNs) over the first 2 weeks posttransplantation. This work demonstrated that CD62L was dispensable for T(reg) -mediated protection from GvHD. ©2010 The Authors Journal compilation©2010 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21070606      PMCID: PMC3208238          DOI: 10.1111/j.1600-6143.2010.03319.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  20 in total

Review 1.  Haematopoietic cell transplantation as immunotherapy.

Authors:  F R Appelbaum
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-28       Impact factor: 11.205

3.  Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors.

Authors:  X Sheng-Tanner; C McKerlie; D Spaner
Journal:  Transplantation       Date:  2000-12-27       Impact factor: 4.939

4.  Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease.

Authors:  Christian A Wysocki; Qi Jiang; Angela Panoskaltsis-Mortari; Patricia A Taylor; Karen P McKinnon; Lishan Su; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

5.  Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells.

Authors:  James M Coghill; Michael J Carlson; Angela Panoskaltsis-Mortari; Michelle L West; Joseph E Burgents; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2010-02-25       Impact factor: 22.113

6.  T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease.

Authors:  J S Serody; S E Burkett; A Panoskaltsis-Mortari; J Ng-Cashin; E McMahon; G K Matsushima; S A Lira; D N Cook; B R Blazar
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

7.  Fas-deficient lpr mice are more susceptible to graft-versus-host disease.

Authors:  M R van Den Brink; E Moore; K J Horndasch; J M Crawford; J Hoffman; G F Murphy; S J Burakoff
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

Review 8.  Homeostatic proliferation and survival of naïve and memory T cells.

Authors:  Onur Boyman; Sven Létourneau; Carsten Krieg; Jonathan Sprent
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

9.  Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD.

Authors:  Joerg Ermann; Petra Hoffmann; Matthias Edinger; Suparna Dutt; Francis G Blankenberg; John P Higgins; Robert S Negrin; C Garrison Fathman; Samuel Strober
Journal:  Blood       Date:  2004-11-16       Impact factor: 22.113

10.  In vitro expansion improves in vivo regulation by CD4+CD25+ regulatory T cells.

Authors:  Jian-Guo Chai; David Coe; Daxin Chen; Elizabeth Simpson; Julian Dyson; Diane Scott
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

View more
  6 in total

1.  High frequencies of CD62L⁺ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation.

Authors:  S-Y Lu; K-Y Liu; D-H Liu; L-P Xu; X-J Huang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

2.  Altered T-cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease.

Authors:  LeShara M Fulton; Nicholas A Taylor; James M Coghill; Michelle L West; Niko Föger; James E Bear; Albert S Baldwin; Angela Panoskaltsis-Mortari; Jonathan S Serody
Journal:  Eur J Immunol       Date:  2014-06       Impact factor: 5.532

3.  Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD.

Authors:  Kaifeng Lisa Lin; LeShara M Fulton; Matthew Berginski; Michelle L West; Nicholas A Taylor; Timothy P Moran; James M Coghill; Bruce R Blazar; James E Bear; Jonathan S Serody
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

Review 4.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

5.  Chronic follicular bronchiolitis requires antigen-specific regulatory T cell control to prevent fatal disease progression.

Authors:  Erica G Schmitt; Dipica Haribhai; Jonathan C Jeschke; Dominic O Co; Jennifer Ziegelbauer; Ke Yan; Yoichiro Iwakura; Manoj K Mishra; Pippa Simpson; Nita H Salzman; Calvin B Williams
Journal:  J Immunol       Date:  2013-10-25       Impact factor: 5.422

6.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.